dc.creator | Koinis F., Xagara A., Chantzara E., Leontopoulou V., Aidarinis C., Kotsakis A. | en |
dc.date.accessioned | 2023-01-31T08:43:28Z | |
dc.date.available | 2023-01-31T08:43:28Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.3390/cells11010020 | |
dc.identifier.issn | 20734409 | |
dc.identifier.uri | http://hdl.handle.net/11615/74936 | |
dc.description.abstract | Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have emerged as a major mediator of immunosuppression in the tumor microenvironment that promotes progression of various tumor types. The main mechanisms under-lying MDSC-induced immunosuppression are currently being explored and strategies to enhance anti-tumor immune response via MDSC targeting are being tested. However, the role of MDSCs in PCa remains elusive. In this review, we aim to summarize and present the state-of-the-art knowledge on current methodologies to phenotypically and metabolically characterize MDSCs in PCa. We describe how these characteristics may be linked with MDSC function and may influence the clinical outcomes of patients with PCa. Finally, we briefly discuss emerging strategies being employed to therapeutically target MDSCs and potentiate the long-overdue improvement in the efficacy of immunotherapy in patients with PCa. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. | en |
dc.language.iso | en | en |
dc.source | Cells | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121460713&doi=10.3390%2fcells11010020&partnerID=40&md5=7d195dab7d26daeee841b4126ace60aa | |
dc.subject | amino acid transporter | en |
dc.subject | chemokine receptor CXCR | en |
dc.subject | cyclooxygenase 2 inhibitor | en |
dc.subject | cytotoxic T lymphocyte antigen 4 | en |
dc.subject | fluorouracil | en |
dc.subject | granulocyte macrophage colony stimulating factor | en |
dc.subject | histone deacetylase inhibitor | en |
dc.subject | interleukin 10 | en |
dc.subject | interleukin 23 | en |
dc.subject | interleukin 4 | en |
dc.subject | interleukin 5 | en |
dc.subject | interleukin 6 | en |
dc.subject | prostaglandin | en |
dc.subject | prostaglandin E2 | en |
dc.subject | reactive nitrogen species | en |
dc.subject | retinoic acid | en |
dc.subject | STAT3 protein | en |
dc.subject | stromal cell derived factor 1 | en |
dc.subject | taurursodiol | en |
dc.subject | adaptive immunity | en |
dc.subject | advanced cancer | en |
dc.subject | antineoplastic activity | en |
dc.subject | B lymphocyte | en |
dc.subject | breast cancer | en |
dc.subject | cancer associated fibroblast | en |
dc.subject | cancer growth | en |
dc.subject | cancer immunotherapy | en |
dc.subject | cancer survival | en |
dc.subject | CD8+ T lymphocyte | en |
dc.subject | cell differentiation | en |
dc.subject | cell function | en |
dc.subject | cell infiltration | en |
dc.subject | cell proliferation | en |
dc.subject | clinical outcome | en |
dc.subject | colon cancer | en |
dc.subject | colorectal cancer | en |
dc.subject | cytotoxic T lymphocyte | en |
dc.subject | cytotoxicity | en |
dc.subject | dendritic cell | en |
dc.subject | disease exacerbation | en |
dc.subject | endothelium cell | en |
dc.subject | epithelial mesenchymal transition | en |
dc.subject | fatty acid oxidation | en |
dc.subject | fibroblast | en |
dc.subject | head and neck cancer | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | immune response | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | lung cancer | en |
dc.subject | lymphoma | en |
dc.subject | male | en |
dc.subject | melanoma | en |
dc.subject | mouse | en |
dc.subject | myeloid-derived suppressor cell | en |
dc.subject | natural killer cell | en |
dc.subject | non small cell lung cancer | en |
dc.subject | nonhuman | en |
dc.subject | outcome assessment | en |
dc.subject | ovary cancer | en |
dc.subject | pancreas cancer | en |
dc.subject | prostate cancer | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | Review | en |
dc.subject | RNA sequence | en |
dc.subject | sarcoma | en |
dc.subject | T lymphocyte | en |
dc.subject | Th17 cell | en |
dc.subject | Th2 cell | en |
dc.subject | thymoma | en |
dc.subject | tumor associated leukocyte | en |
dc.subject | tumor immunity | en |
dc.subject | tumor microenvironment | en |
dc.subject | tumor-associated macrophage | en |
dc.subject | upregulation | en |
dc.subject | immunology | en |
dc.subject | immunotherapy | en |
dc.subject | myeloid-derived suppressor cell | en |
dc.subject | pathology | en |
dc.subject | phenotype | en |
dc.subject | prostate tumor | en |
dc.subject | Humans | en |
dc.subject | Immunosuppression Therapy | en |
dc.subject | Immunotherapy | en |
dc.subject | Male | en |
dc.subject | Myeloid-Derived Suppressor Cells | en |
dc.subject | Phenotype | en |
dc.subject | Prostatic Neoplasms | en |
dc.subject | Tumor Microenvironment | en |
dc.subject | MDPI | en |
dc.title | Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives | en |
dc.type | other | en |